ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin
about
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for interventionEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerTargeting the adaptive molecular landscape of castration-resistant prostate cancerN-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate CancerFluorescence in situ hybridization in surgical pathology: principles and applications.Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.Utility of FDG-PET in clinical neuroendocrine prostate cancer.Integrative molecular profiling of routine clinical prostate cancer specimens.Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification.N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatmentA basal stem cell signature identifies aggressive prostate cancer phenotypes.miR-539 inhibits prostate cancer progression by directly targeting SPAG5A case of the large cell neuroendocrine carcinoma of the urinary bladder.Intravenous renal cell transplantation for rats with acute and chronic renal failure.Long term disease free survival with multimodal therapy in small cell bladder cancer.Histological variants of prostatic carcinoma and their significance.Diagnostic and prognostic molecular biomarkers for prostate cancer.Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma.The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencingMolecular cytogenetics: recent developments and applications in cancer.ERG protein expression as a biomarker of prostate cancer.Small cell carcinoma of the prostate.Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective.Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.Potential for targeted therapy in prostate cancers with ERG abnormalities.ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies.Next generation patient-derived prostate cancer xenograft models.Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.Proposed morphologic classification of prostate cancer with neuroendocrine differentiation.Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.
P2860
Q21129293-D69E8853-2A43-4E45-906B-4FA05DD61875Q26777310-6F2F130D-9399-4934-9FF9-62AFA010BEDAQ27022821-A298A145-2CCC-4BB9-B7EF-79609EB5C9AAQ28771715-59CB8D36-63EC-4E4E-8F8A-7575A3FF99DCQ33593910-2F23978C-1407-4803-B0BA-93C432A105D9Q34186632-6638E16D-93E1-4F60-8AE3-E2BD170BF091Q34216236-03127D0F-AF24-441E-AA53-2DB5726B28F3Q35166475-0EDFC049-AD77-42C4-A973-B26118B51B25Q35892022-4EA4CBE6-1F26-4E56-A2A0-BFD7DEB18335Q35925835-F5C996F6-7F9C-4748-822C-E0802E646242Q35980945-C9A6CBE6-A5CB-4055-86DE-18371668A611Q36131601-EBD511E5-EF97-4251-AC8A-78BD38420760Q36332070-0229F115-2E30-47F6-BFC1-975C90EA7BD7Q36758507-5702B534-BFBB-4DCD-A172-164337EA84B4Q36801653-15C44E9B-E545-4A6D-8D6C-0704B7289615Q37174752-1A825CE8-5FB3-4DC5-9A4B-9A5E6CCCFD97Q37340577-AED4A03B-A2F0-4DB2-8B30-C81F9C186C21Q37972700-4C176FBB-7A80-41C5-B63B-31F8A475B981Q37972703-71D85FAC-9208-476F-987C-253C47848574Q38068866-308973C6-5968-4655-9A02-BEEEF281E7F7Q38090427-A91FE838-3707-4D3C-9C6E-8FD57F796CEBQ38119502-466CC31A-7CA9-4618-B433-89CEEB6F162AQ38165243-0282388E-23F4-4DFE-99BD-9360F908B1E8Q38188869-4CD5CD37-4483-44B1-8EDE-82079406192EQ38722705-E60D3325-9971-459E-84DA-A2928F4594B6Q38849534-465AF02E-2502-4306-97E4-3FC056B0198AQ38865487-BC019692-2FA7-483D-AF39-0D95750BB95EQ38930155-B85D8D8C-DDE6-4372-A089-140FD8EFEBE0Q39016544-79E5A207-B552-42D1-AD14-A05254C284EAQ39044979-3BB60783-237A-4B31-85CD-D92EB825573BQ39214638-5B93BC31-3D78-4A1A-88C6-1B747F89EC12Q39385550-C1B86898-2375-4B6A-9B91-BA096734B057Q39501622-C3459026-F7C0-4406-B66C-1F91FDC157EEQ39666134-AC5F585C-B5EC-4BE8-B1BA-7BCC919E7ACBQ39673894-D50917DB-0116-4A98-BC04-BCF4746D6390Q41830742-8C30B0FF-6871-4253-883D-5C240CDBB4EBQ41994427-8CDEBFF6-623D-4AAA-9D23-5B9B284D51E6Q42184220-CFAEE211-DE6C-477A-8557-BB6FBD83C0BBQ42287150-9CD3D7E7-3FB3-4E89-BDE0-A6D66526B9F5Q42593140-44CF3BCD-4B3E-4F65-AE91-4414EE603B2B
P2860
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@ast
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@en
type
label
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@ast
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@en
prefLabel
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@ast
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@en
P2093
P2860
P1433
P1476
ERG-TMPRSS2 rearrangement is s ...... e supporting monoclonal origin
@en
P2093
Adeboye O Osunkoya
Antonio Lopez-Beltran
Gregory T MacLennan
Jiaoti Huang
Jorge L Yao
Liang Cheng
Shaobo Zhang
Steven Shen
P2860
P2888
P304
P356
10.1038/MODPATHOL.2011.56
P577
2011-04-15T00:00:00Z
P5875
P6179
1036197257